statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Expert Outlook: Tango Therapeutics Through The Eyes Of 6 Analysts

Latest Ratings for TNGX
 DateFirmActionFromTo Sep 2021SVB LeerinkInitiates Coverage OnOutperform Sep 2021WedbushInitiates Coverage OnOutperform Sep 2021GuggenheimInitiates Coverage OnBuy
 View...

Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara...

Forecasting The Future: 4 Analyst Projections For Tango Therapeutics

Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity

Tango Therapeutics halts its TNG348 program due to liver toxicity issues found in dose escalation studies. The company will now focus on its PRMT5 program and plans to update on TNG908 and TNG462...

Medivirs licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

Medivirs licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program Medivirs licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program...

Tango Therapeutics Announces Discontinuation of TNG348 Program

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that it will...

Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial...

Tango Therapeutics (NASDAQ:TNGX) Now Covered by Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of Tango Therapeutics (NASDAQ:TNGX - Free Report) in a research note issued to investors on Thursday morning, MarketBeat Ratings reports. The firm...

Tango Therapeutics initiated with bullish view at Cantor Fitzgerald

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Tango Therapeutics (TNGX, $7.65) RSI Indicator left the oversold zone on April 01, 2024

This is a signal that TNGX's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.

Volume	920,807.00
52-Wk High	$13.03
52-Wk Low	$3.05

TNGX Tango Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals